Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We enclose copies of Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended December 31, 2022 published on February 01, 2023 in MINT (English) and HINDUSTAN (Hindi). Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that audio recording of investors' conference call for Un-audited financial results for the quarter ended December 31, 2022 held on Tuesday, January 31, 2023, has been uploaded on the Company''s website.
Jubilant Ingrevia Results Earnings Call for Q3FY23
Conference Call with Jubilant Ingrevia Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript. Jubilant Ingrevia Ltd - 543271 - Corporate Action - Fixed Record Date As February 10, 2023 For Interim Dividend
The Board has declared an Interim Dividend of Rs.2.50 per equity share of Re. 1 each on the paid-up Equity Share capital of the Company for the Financial Year 2022-23. Further, in terms of Regulation 42 of the Listing Regulations, the Board has fixed Friday, February 10, 2023 as 'Record Date' for the purpose of ascertaining eligibility of the shareholders for payment of Interim Dividend. The Interim Dividend will be paid/ dispatched on or before March 1, 2023. Q3FY23 Quarterly Result Announced for Jubilant Ingrevia Ltd.
Specialty Chemicals firm Jubilant Ingrevia announced Q3FY23 results: Consolidated Q3FY23: Overall revenue is 10% lower on YoY basis, mainly on account of lower sales performance of the Nutrition & Health Solution Business, while volumes in Specialty Chemicals products and Acetic Anhydride continue to improve. Speciality Chemicals revenue grew by 34% YoY, driven by higher price realization and volume growth across product segments. In Nutrition and Health Solutions business Niacinamide (Vitamin B3) continued to witness lower demand owing to flu impact leading to lower realization, though we have improved our volumes sequentially. Chemical intermediates revenue is lower, mainly impacted on account of lower prices of key feedstock (Acetic Acid). Though we continue to increase our volume of Acetic Anhydride. EBITDA is at Rs 158 Crore. Though Specialty Chemical EBDITA improved, the overall impact is mainly due to significantly lower profitability in the Nutrition business and non-availability of contracted coal leading to higher energy cost. Lower EBITDA also resulted in lower profit after tax. ROCE for the quarter stood at 16.3% on TTM basis, as against 27.8% in FY22. ROE during the quarter stood at 12.7% on TTM basis, as against 21.9% in FY22. Commenting on the Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, CoChairman, Jubilant Ingrevia Limited said: “We are pleased to announce stable performance during the quarter under review, amidst the continuing headwinds of higher energy costs and challenging global market situation. We are also glad to share that the Board has recommended interim dividend of 250% i.e. Rs 2.50 per equity share of face value of Rs 1 each for the FY23. This shall result in cash outflow of Rs 39.8 Crore. We are pleased to inform that our Specialty Chemicals Business revenue grew by 34% YoY and absolute EBIDTA grew by 15% YoY driven by higher volumes and improved price realization. In Nutrition & Health Solution business the demand for Niacinamide (Vitamin B3) continue to be subdued impacting our price realization though we have improved our volumes sequentially. The flu situation in EU and US regions is still continuing, though the situation is improving in EU region. The demand-related challenges of Vitamin B3 are short-term and we continue to remain focused towards improving our presence in food and cosmetics segment. In Chemical Intermediates Business the revenue on YoY basis is impacted due to lower prices of feedstock (Acetic Acid), leading to lower sales prices of Acetic Anhydride and Ethyl Acetate. However, we continue to improve our volumes and market share of Acetic Anhydride globally. The company has firm plans to significantly reduce overall energy cost in a phased manner through various initiatives by sourcing power from Grid and renewable sources, optimizing coal consumption through efficiency improvement in consumption as well as in generation. We continue to focus on our growth plans through new products and platforms and we are committed to deliver robust growth in the future.” Result PDF Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Date of payment of Dividend
Outcome of Board Meeting Jubilant Ingrevia Ltd - 543271 - Board Meeting Outcome for Outcome Of Board Meeting
Please find attached the outcome of the Board Meeting Jubilant Ingrevia Ltd - 543271 - Corporate Action-Board approves Dividend
Outcome of the Board Meeting Jubilant Ingrevia Ltd - 543271 - Outcome Of The Board Meeting
Please find attached herewith the outcome of the Board Meeting Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Company is organizing a Conference Call on January 31, 2023 after submission of the financial results for the quarter ended December 31, 2022 to the Stock Exchanges. Details of the Conference Call are attached.